Zynerba Pharmaceuticals — Investor Presentation (April 2020)
42 slides from Zynerba Pharmaceuticals's investor presentation, Apr 15, 2020
Slide 1: Corporate Overview April 15, 2020
Corporate Overview April 15, 2020
Slide 2: Forward-Looking Statements
Forward - Looking Statements 2 © 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE S
Slide 3: A Rare/Near-Rare Neuropsychiatric Company
Zynerba Pharmaceuticals (NASDAQ: ZYNE) 3 A Rare/Near - Rare Neuropsychiatric Company • Deep pipeline focused on high unmet medical needs; translating into multi - billion dollar market opportunity with Zygel™(CBD gel) • Four clinical shots on goal: FXS, DEE, ASD, 22q • Enrollment complete in pivotal
Slide 4: COVID-Preparedness
COVID - 19 Preparedness 4 • We believe we have made smart and actionable adjustments in response to COVID - 19: • These include remote site monitoring and remote visits using telemedicine where needed • Our approach is consistent with FDA’s Guidance on Conduct of Clinical Trials of Medical Products
Slide 5: Deep Clinical Pipeline
Deep Clinical Pipeline 5 *Orphan Drug Designation Zygel Cannabidiol Gel Expected Milestones Topline pivotal data in late 2Q2020 Topline Phase 2 data in 2Q2020 Topline Phase 2 data in 3Q2020 Discussions with FDA in 1H2020 to define clinical path forward
Slide 6: Zygel (ZYN002) Cannabidiol Gel
Neuropsych Indications Differentiated Formulation delivers CBD through the epidermis and into the circulatory system Zygel (ZYN002) Cannabidiol (CBD) Gel 6 Unique MOA First & only patent - protected, permeation - enhanced, pharmaceutically - produced CBD gel Transdermal CBD modulates multiple recept
Slide 7: Fragile X Syndrome (FXS)
Fragile X Syndrome (FXS) 7
Slide 8: Fragile X Syndrome (FXS) Overview
Fragile X Syndrome (FXS) Overview 8 • Rare genetic developmental disability • Leading known cause of both inherited intellectual disability and autism spectrum disorder • Symptoms linked to deficiencies in the endocannabinoid (EC) system • System of neurotransmitters regulating emotional responses,
Slide 9: FAB-C Open Label Phase 2 Trial Design
Day 1 to Week 6 Week 7 to 12 Up to 24 months FAB - C Open Label Phase 2 Trial Design 9 Treatment of F ragile X Syndrome A nxiety and B ehavioral C hallenges with CBD Titration Maintenance Screening Open label extension Dosing initiated at 50 mg Zygel daily; may be titrated up to 250 mg Zygel daily D
Slide 10: Data From Three Month FAB-C Phase 2 Trial
Data From Three Month FAB - C Phase 2 Trial 10 0 10 20 30 40 50 60 70 Social Avoidance Irritability Socially Unresponsive / Lethargic Inappropriate Speech Stereotypy Hyperactivity Month 3 (n=18) Baseline: 18.2 Baseline: 14.5 Baseline: 8.7 Baseline: 5.1 Baseline: 7.9 Baseline: 6.1 41.8% 52.9% 54.9% 3
Slide 11: Third Party Data Suggest Placebo Rate
Third Party Data* Suggest PBO Rate of 10 to 18 Percent 11 0 10 20 30 40 50 60 Zygel 0 10 20 30 40 50 Zygel 0 10 20 30 40 50 60 Zygel 0 10 20 30 40 50 Zygel 0 10 20 30 40 50 60 Zygel 0 10 20 30 40 Zygel Socially Unresponsive / Lethargic Does not pay attention Inappropriate Speech Repeats words / phra
Slide 12: Sustained Improvements Through 12 Months of Treatment
Three Month FAB - C Data vs. 12 Months of Treatment 12 0 10 20 30 40 50 60 70 80 90 Social Avoidance Irritability Socially Unresponsive Hyperactivity Stereotypy Inappropriate Speech Month 3 (n=12) Month 12 (n=9) 57.9* 51.1* 65.7* 36.7* 60.8* 56.5* *P ≤ 0.05 Mean % Improvement from Baseline 77.2* 59.
Slide 13: FAB-C Open Label Phase 2 Trial Safety Summary
FAB - C Open Label Phase 2 Trial 13 • Well tolerated, consistent with previously reported data; no SAEs • No clinically meaningful trends in vital signs, ECG, or clinical safety labs including LFTs; no THC detected in plasma • Discontinuations • Two siblings discontinued in Period 1 • One for worsen
Slide 14: Estimating the Health State Utility (HUI) Score for FXS
FAB - C Open Label Phase 2 Trial 14 Estimating the Health State Utility (HUI) Score for FXS and Potential Benefit of Treatment with Zygel Mean ABC - UI Score at Each Timepoint during Treatment with Zygel (*P<0.01) Data reported at the American Society for Experimental Neurotherapeutics (ASENT) 2020
Slide 15: CONNECT-FX: A Pivotal Trial In FXS
CONNECT - FX: A Pivotal Trial In FXS 15 C linical study O f Ca NN abidiol (CBD) in Childr E n and Adoles C en T s with F ragile X (CONNECT - FX) Zygel 250 mg daily 500 mg daily (weight - based dose) Placebo Mirrors Zygel administration Patients randomized (1:1) to receive either Zygel or placebo Tre
Slide 16: CONNECT-FX: Endpoints
CONNECT - FX: A Pivotal Trial In FXS 16 • Primary endpoint: • Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale • Key secondary endpoints: • Change from baseline to end of the treatment in • ABC - C FXS Irritability subscale score • ABC - C FXS Socially Unresponsive/L
Slide 17: CONNECT-FX Demographics
CONNECT - FX Demographics 17 Patients n Randomization: Enrollment complete 212 Number of male patients 159 (75%) Mean age at randomization in study 9.7 years Completed 14 - week Tx period (as of 3/9/2020) 163 Percent of completed patients enrolling in CONNECT - FX OLE 97%
Slide 18: Baseline Behavior Severity: CONNECT-FX vs Ph2 FAB-C
Baseline Behavior Severity: CONNECT - FX vs Ph2 FAB - C 18 Prospective inclusion criteria expected to provide a more severely impacted population which we believe should enhance ability to demonstrate a strong signal of activity and minimize response variability Note : Higher baseline scores denote
Slide 19: CONNECT-FX: Path to NDA
CONNECT - FX 19 • With positive results in pivotal trial, Zynerba intends to request a meeting with the FDA to: • Determine acceptability of data as basis for NDA filing by YE 2020 • Seek advice on marketing authorization preparation • Potential approval by mid - year 2021 • Zynerba believes the ind
Slide 20: Improvements in Behavior May Provide Read-Through to Other Zygel Studies
20 • Presented data at SSBP* showing constellation of shared socio - behavioral symptoms in ASD, FXS, and 22q11.2DS • These include anxiety leading to: • Isolation and social avoidant behaviors • Irritability • Attention deficits • Poor communication Improvements in Behavior May Provide a Read - Thr
Slide 21: Autism Spectrum Disorder (ASD) in pediatric patients
21 Autism Spectrum Disorder (ASD) in pediatric patients
Slide 22: ASD in Pediatrics Overview
ASD in Pediatrics Overview 22 • Near - rare disorder affecting ~1MM pediatric and adolescent pts • DSM - 5 diagnosis • Includes Autistic disorder, Asperger’s syndrome, and Pervasive Development Disorder - not otherwise specified (PDD - NOS) • Symptoms include • Anxiety • Restricted, repetitive patte
Slide 23: Developing Zygel in ASD
Developing Zygel in ASD 23 • Newer studies suggest ASD is linked to disruption in the EC system • Altered anandamide signaling may contribute to ASD - related social and communication impairments • EC system modulates many cellular functions and molecular pathways altered in ASD: imbalanced GABAergi
Slide 24: BRIGHT Phase 2 Trial in ASD
BRIGHT Phase 2 Trial in ASD 24 Open - La B el Tole R ab I lity and Efficacy Study of ZYN002 Administered as a Transdermal G el to C H ildren and Adolescen T s with Autism Spectrum Disorder Target: 36 patients; 37 enrolled Four through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14
Slide 25: Baseline Patient Demographics
Baseline Patient Demographics Demographic BRIGHT Patients N = 37 Age, years Mean (range) 9.2 (3 - 16) Sex, n (%) Male Female 34 (91.9) 3 (8.1) Race, % White Aboriginal Asian Other 75.7 5.4 8.1 10.8 BRIGHT Trial Patient Demographics
Slide 26: Baseline Disease Characteristics
26 Baseline Disease Characteristics ABC - C Irritability Subscale score (0 - 45) n Mean (range) 37 30.0 (18 - 43) ADOS® - 2 comparison score n Mean (range) <5 (mild ASD), n (%) 5 - 7 (moderate ASD), n (%) 8 - 10 (severe ASD), n (%) 36 7.5 (4 - 10) 2 (5.6) 19 (52.8) 15 (41.7) DSM - 5 severity level L
Slide 27: 22q11.2 Deletion Syndrome (22q)
22q11.2 Deletion Syndrome (22q) 27
Slide 28: 22q Overview
22q Overview 28 • Most common contiguous gene deletion syndrome • Rare disorder: ~81K patients in US • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in infancy • Neuropsychiatric illnesses (anxiety disorders, ASD) and learning disabilities
Slide 29: 22q Patient Management
22q Patient Management 29 • Two primary stages of 22q patient management: • During infancy, doctors address acute physical concerns, such as anomalies of heart and palate, with surgery • Once the physical concerns are stabilized, focus shifts to managing neuropsychiatric symptoms, such as anxiety an
Slide 30: Developing Zygel in 22q
Developing Zygel in 22q 30 • CBD may treat neuropsychiatric symptoms in 22q due to activity as: • Modulator of endocannabinoid system • Agonist at serotonin 1A receptors • Antagonist at GPR55 receptors • Early control of anxiety may delay the development of psychosis • Phase 2 study underway in pedi
Slide 31: INSPIRE Phase 2 Trial in 22q
INSPIRE Phase 2 Trial in 22q 31 Target: 20 patients Six through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks 250 mg to 500 mg daily Efficacy assessments (week 14 vs baseline) include: • Aberrant Behavior Checklist - Community (ABC - C) • Anxiety, Depression and Mood Scale (
Slide 32: DEE Developmental and Epileptic Encephalopathies
DEE Developmental and Epileptic Encephalopathies 32
Slide 33: DEE Patients are Medically Fragile
DEE Patients are Medically Fragile 33 • Group of rare / ultra rare childhood - onset epilepsies with impaired or regressed developmental progress • Cognitive impairment, psychiatric problems, and behavioral disturbances are phenotypic • Medically fragile population • Comorbidities include cerebral p
Slide 34: BELIEVE Phase 2 Trial in DEE
BELIEVE 1 Phase 2 Trial in DEE 34 Open La B el Study to Assess the Safety and E fficacy of ZYN002 Administered as a Transderma L Gel to Ch I ldren and Adol E scents with De V elopmental and E pileptic Encephalopathy 48 patients enrolled Three through 17 years of age Screening Maintenance 22 Weeks Ti
Slide 35: BELIEVE 1: Clinically Meaningful Seizure Reductions
35 BELIEVE 1: Clinically Meaningful Seizure Reductions from Baseline and Sustained through Six Months in DEE 0 10 20 30 40 50 60 70 Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Median Percent Reduction from Baseline, FIAS and CS N=33 N=33 N=33 N=32 N=32 N=29 16 44 44 47 58 51 0 10 20 30 40 50 60
Slide 36: BELIEVE 1 Safety: Well Tolerated in this Six Month Trial
36 • All events in six month period, whether unrelated or related to study, drug are reported as adverse events (AEs) (e.g.: influenza, runny nose, ingrown toenail, scrapes, etc.) • AEs common in this medically fragile population, and expected in a six - month trial • As a result, most patients expe
Slide 37: BELIEVE 1: Qualitative Assessments of Behavioral and Cognitive Improvements
37 • Parents and caregivers provided qualitative assessment on their child’s overall experiences with Zygel • Improvements were seen in seizure intensity and duration, and socio - behavioral and cognitive impairments • Improvements in >25% of children: • 58% reported improved vitality (e.g. alertnes
Slide 38: Compelling Results Suggest a Pathway to Pivotal Trials
38 • Efficacy results: • Clinically meaningful reductions in seizures beginning in month two and sustained through six months • Suggest improvements on important behavioral symptoms • Safety results: • Zygel was well tolerated • Consistent with previously reported Zygel studies • Zynerba approach to
Slide 39: Planned Approach to FDA
39 Syndromes and encephalopathies Dravet LGS West Early myoclonioc epilepsy Hypoxic - ischemic enceph . Seizure type Focal Impaired Awareness Bilateral Tonic Clonic Generalized Tonic Clonic Focal aware Absence Convulsive Other Seizure types Consciousness impairing seizures Doose Ohtahara Landau - Kl
Slide 40: Financial Strength
Financial Strength 40 • Clean balance sheet • No debt, 23.6M shares outstanding (as of March 4, 2020) • Cash and cash equivalent position of $70.1M as of December 31, 2019 • Cash runway expected to be sufficient to fund operations and capital requirements into the second half of 2021 • Beyond the ex
Slide 41: Expected Clinical Milestones in 2020
Expected Clinical Milestones in 2020 41 FXS DEE Report pivotal CONNECT - FX topline results ASD 22q 1Q 2020 2Q 2020 Report Ph. 2 BRIGHT topline results Report Ph. 2 INSPIRE topline results 3Q 2020 4Q 2020 Discussions with FDA to define clinical path forward NDA submission
Slide 42: Corporate Overview April 15, 2020
Corporate Overview April 15, 2020
Zynerba Pharmaceuticals — Investor Presentation (April 2020) on 6ix